Benitec Biopharma Ltd Stock Buy Hold or Sell Recommendation
| BNTC Stock | USD 6.86 0.14 2.08% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Benitec Biopharma Ltd is 'Strong Hold'. Macroaxis provides Benitec Biopharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BNTC positions. The advice algorithm takes into account all of Benitec Biopharma's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Benitec Biopharma's buy or sell advice are summarized below:
Real Value 6.01 | Target Price 6 | Hype Value 7.4 | Market Value 6.86 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Benitec Biopharma Ltd given historical horizon and risk tolerance towards Benitec Biopharma. When Macroaxis issues a 'buy' or 'sell' recommendation for Benitec Biopharma Ltd, the advice is generated through an automated system that utilizes algorithms and statistical models.
Benitec |
Execute Benitec Biopharma Buy or Sell Advice
The Benitec recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Benitec Biopharma Ltd. Macroaxis does not own or have any residual interests in Benitec Biopharma Ltd or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Benitec Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Solid | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Excited | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Benitec Biopharma Trading Alerts and Improvement Suggestions
| Benitec Biopharma is way too risky over 90 days horizon | |
| Benitec Biopharma appears to be risky and price may revert if volatility continues | |
| Benitec Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 75 K. Net Loss for the year was (19.56 M) with profit before overhead, payroll, taxes, and interest of 75 K. | |
| Benitec Biopharma Ltd currently holds about 4.06 M in cash with (18.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5. | |
| Benitec Biopharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 55.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: JMP lifts Benitec share price target on positive BB-301 data |
Benitec Biopharma Returns Distribution Density
The distribution of Benitec Biopharma's historical returns is an attempt to chart the uncertainty of Benitec Biopharma's future price movements. The chart of the probability distribution of Benitec Biopharma daily returns describes the distribution of returns around its average expected value. We use Benitec Biopharma Ltd price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Benitec Biopharma returns is essential to provide solid investment advice for Benitec Biopharma.
| Mean Return | 1.51 | Value At Risk | -6.35 | Potential Upside | 12.45 | Standard Deviation | 7.56 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Benitec Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Benitec Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Benitec Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Benitec Biopharma Ltd backward and forwards among themselves. Benitec Biopharma's institutional investor refers to the entity that pools money to purchase Benitec Biopharma's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rhumbline Advisers | 2023-12-31 | 186 | Group One Trading, Lp | 2023-12-31 | 89.0 | Wells Fargo & Co | 2023-12-31 | 17.0 | State Street Corporation | 2023-09-30 | 0.0 | Rosenberg Matthew Hamilton | 2023-12-31 | 0.0 | Private Advisor Group, Llc | 2023-09-30 | 0.0 | Northern Trust Corp | 2023-09-30 | 0.0 | Virtu Financial Llc | 2023-09-30 | 0.0 | Wealthtrust Axiom Llc | 2023-09-30 | 0.0 | Franklin Resources Inc | 2023-12-31 | 588.2 K | Suvretta Capital Management, Llc | 2023-12-31 | 204.2 K |
Benitec Biopharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (5.9M) | 10.0M | (15.7M) | (1.6M) | (1.4M) | (1.4M) | |
| Free Cash Flow | (7.6M) | (13.1M) | (15.9M) | (18.0M) | (16.2M) | (17.0M) | |
| Other Non Cash Items | 2K | (16K) | 10K | 717K | 824.6K | 865.8K | |
| Capital Expenditures | 95K | 221K | 13K | 1K | 900.0 | 855.0 | |
| Net Income | (8.3M) | (13.9M) | (18.2M) | (19.6M) | (17.6M) | (16.7M) | |
| End Period Cash Flow | 9.8M | 19.8M | 4.1M | 2.5M | 2.2M | 2.1M | |
| Depreciation | 374K | 424K | 392K | 381K | 438.2K | 240.6K | |
| Change To Netincome | 239K | 618K | 880K | 455K | 409.5K | 591.5K | |
| Change To Inventory | (700K) | (83K) | (1.1M) | (1.3M) | (1.2M) | (1.1M) | |
| Investments | (94K) | (221K) | (13K) | (1K) | (1.2K) | (1.2K) |
Benitec Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Benitec Biopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Benitec Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Benitec stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 1.43 | |
β | Beta against NYSE Composite | 0.85 | |
σ | Overall volatility | 7.77 | |
Ir | Information ratio | 0.19 |
Benitec Biopharma Volatility Alert
Benitec Biopharma Ltd is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Benitec Biopharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Benitec Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Benitec Biopharma Fundamentals Vs Peers
Comparing Benitec Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Benitec Biopharma's direct or indirect competition across all of the common fundamentals between Benitec Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Benitec Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Benitec Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Benitec Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Benitec Biopharma to competition |
| Fundamentals | Benitec Biopharma | Peer Average |
| Return On Equity | -1.78 | -0.31 |
| Return On Asset | -0.82 | -0.14 |
| Operating Margin | (355.61) % | (5.51) % |
| Current Valuation | (2.53 M) | 16.62 B |
| Shares Outstanding | 2.59 M | 571.82 M |
| Shares Owned By Insiders | 6.80 % | 10.09 % |
| Shares Owned By Institutions | 55.14 % | 39.21 % |
| Number Of Shares Shorted | 10.96 K | 4.71 M |
| Price To Earning | (5.10) X | 28.72 X |
| Price To Book | 0.92 X | 9.51 X |
| Price To Sales | 233.74 X | 11.42 X |
| Revenue | 75 K | 9.43 B |
| Gross Profit | 75 K | 27.38 B |
| EBITDA | (18.73 M) | 3.9 B |
| Net Income | (19.56 M) | 570.98 M |
| Cash And Equivalents | 4.06 M | 2.7 B |
| Cash Per Share | 0.50 X | 5.01 X |
| Total Debt | 559 K | 5.32 B |
| Debt To Equity | 0.28 % | 48.70 % |
| Current Ratio | 1.90 X | 2.16 X |
| Book Value Per Share | 5.97 X | 1.93 K |
| Cash Flow From Operations | (18.01 M) | 971.22 M |
| Short Ratio | 0.55 X | 4.00 X |
| Earnings Per Share | (236.13) X | 3.12 X |
| Target Price | 10.0 | |
| Number Of Employees | 16 | 18.84 K |
| Beta | 1.02 | -0.15 |
| Market Capitalization | 56.06 M | 19.03 B |
| Total Asset | 4.46 M | 29.47 B |
| Retained Earnings | (167.89 M) | 9.33 B |
| Working Capital | (249 K) | 1.48 B |
| Current Asset | 19.38 M | 9.34 B |
| Current Liabilities | 1.03 M | 7.9 B |
Note: Acquisition by Megan Boston of 200004 shares of Benitec Biopharma at 5.21 subject to Rule 16b-3 [view details]
Benitec Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Benitec . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 1766.84 | |||
| Daily Balance Of Power | 0.2979 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 6.81 | |||
| Day Typical Price | 6.82 | |||
| Price Action Indicator | 0.13 | |||
| Period Momentum Indicator | 0.14 |
About Benitec Biopharma Buy or Sell Advice
When is the right time to buy or sell Benitec Biopharma Ltd? Buying financial instruments such as Benitec Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 400K | 3.7M | 4.3M | 4.5M | Total Assets | 6.0M | 4.5M | 4.0M | 3.8M |
Use Investing Ideas to Build Portfolios
In addition to having Benitec Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Municipals ETFs Thematic Idea Now
Broad Municipals ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Municipals ETFs theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Municipals ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Benitec Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Benitec Stock analysis
When running Benitec Biopharma's price analysis, check to measure Benitec Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Benitec Biopharma is operating at the current time. Most of Benitec Biopharma's value examination focuses on studying past and present price action to predict the probability of Benitec Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Benitec Biopharma's price. Additionally, you may evaluate how the addition of Benitec Biopharma to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Benitec Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (236.13) | Revenue Per Share 0.03 | Quarterly Revenue Growth 0.125 | Return On Assets (0.82) | Return On Equity (1.78) |
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.